At the Israeli Society for Vision and Eye Research (ISVER) conference, the MedInsight Research Institute and Center for Drug Repurposing at Ariel University presented the latest findings on positive user-reported outcomes of the repurposed drug dipyridamole in treating pterygium and related dry-eye symptoms.
Pterygium, or Surfer’s Eye, is a benign growth that affects 10% of the population worldwide. An early-stage pterygium is known as a pinguecula, and affects 50% of the population. Besides being unsightly, pterygium and pinguecula often become inflamed and cause dry eye. Eventually, they can completely obstruct vision. Until now the only treatment for pterygium has been surgical removal, which involves a high recurrence rate or a topical steroid that often results in glaucoma. The cardiovascular drug Dipyridamole has been used for the past 55 years for treating angina and preventing stroke but is now a promising potential treatment for this very difficult to treat disorder.
It appears to be not only effective, but entails only a small amount of a very safe medicine. Learn more about this drug repurposing trial.